April 2026 Special Prescription Drug Affordability Board Meeting

Meeting Details

• Date and time: April 13th, 2026 9:00 am

Public Comment

The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected]​ no later than the close of business on Wednesday, April 8, 2026, and provide:

1. Your name
2. Your address
3. The agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

Written Comment

The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]​​​. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, April 8, 2026. Please utilize the subject line “April 2026 Board Comments.”

Agenda and Meeting Materials

• Agenda - PDF - 119.81 KB
• Meeting Recording
• Minutes - PDF - 144.4 KB
• Consideration of Proposed COMAR 14.01.06 - Implementation and Monitoring of Upper
  Payment Limits
  • Proposed COMAR 14.01.06- Implementation and Monitoring of Upper Payment Limits (Clean) - PDF - 102.92 KB
  • Proposed COMAR 14.01.06- Implementation and Monitoring of Upper Payment Limits (Redlined) - PDF - 85.79 KB
  • UPL Regulations- General Provisions (Presentation) - PDF - 142.67 KB
  • Written Comments​ Received on March 30, 2026
    • Written Comment Packet - PDF - 1.46 MB

 Farxiga - Consideration of Final Cost Review Study Report, Policy Review, and UPL

• Farxiga- Cost Review Study Report (Presentation)​ - PDF - 171.75 KB
• ​Farxiga- Cost Review Study Report (Clean) with Appendix A-C ​REDACTED​ - PDF - 16.51 MB
  • ​​Appendix A Excel Exhibits:
    • Exhibit 3​ ​Farxiga Therapeutic Alternative Pricing REDACTED - XLSX - 315.17 KB
    • Exhibit 4 Farxiga Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics​​ - XLSX - 150.25 KB
    • Exhibit 5
      • Exhibit 5A Farxiga Summary of Cost Effectiveness Analyses - XLSX - 27.66 KB
      • Exhibit 5B Farxiga Summary of Comparative Effectiveness Research  - XLSX - 64.44 KB
• Farxiga- Policy Review Process and Non- UPL Policies (Presentation) - PDF - 203.47 KB
  • ​Non-UPL Policy- WAC Penalty​ - PDF - 142.77 KB
  • Non-UPL​ Policy- PBM Reimbursement- Delinking or Flat Fee​ - PDF - 115.24 KB
  • Non- UPL Policy- Navigator Program​ - PDF - 114.11 KB
• Farxiga- Consideration of Upper Payment Limit (Presentation) - PDF - 212.83 KB
• ​​​Proposed COMA​R 14.01.07.01- Farxiga Upper Payment Limit - PDF - 93.48 KB
• Farxiga: Calculations and Analyses Underpinning Potential Upper Payment Limit (UPL) Values ​​Clean Version 2.0 - PDF - 185.32 KB
• Farxiga: Calculations a​nd Analyses Underpinning Potential Upper Payment Limit (UPL) Values ​Tracked Version 2.1​ - PDF - 187.05 KB
• Comments Received by March 4, 2026 on Farxiga UPL Amount and Methodology Document
  • ​Written Comment Packet - PDF - 1.35 MB
• Comments Received by April 6, 2026 on Farxiga: Calculations and Analyses Underpinning Potential Upper Payment Limit (UPL) Values
  • Written Comment Packet - PDF - 1.05 MB

 Jardiance - Consideration of Final Cost Review Study Report, Policy Review, and UPL

• Jardiance- Cost Review Study Report (Presentatio​n)​ - PDF - 151.37 KB
• 4.13.2026 Jardiance Cost Review Study Report - PDF - 6.02 MB
  • ​​​Appendix A Excel Exhibits:​
    • Exhibit 3​ ​Jardiance Therapeutic Alternative Pricing REDACTED - XLSX - 315.15 KB
    • Exhibit 4 Jardiance Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics - XLSX - 150.29 KB
    • Exhibit 5
      • Exhibit 5A Jardiance Summary of Co​st Effectiveness Analyses - XLSX - 117.71 KB
      • Exhibit 5B Jardiance Summary of Comparative Effectiveness Research - XLSX - 60.49 KB  ​​​
• Jardiance- Policy Review Process and Non- UPL Policies (Presentation) - PDF - 203.47 KB
  • ​Non-UPL Policy- WAC Penalty​ - PDF - 142.77 KB
  • Non-UPL​ Policy- PBM Reimbursement- Delinking or Flat Fee​ - PDF - 115.24 KB
  • Non- UPL Policy- Navigator Program​ - PDF - 114.11 KB
• Jardiance- Consideration of Upper Payment Limit (Presentation) - PDF - 212.49 KB
• Proposed COMAR 14.01.07.​02​- Jardiance Upper Payment Limit​​​ ​​ - PDF - 92.86 KB
• Jardiance: Calculations and Analyses Underpinning Potential Upper Payment Limit (UPL) Values​​ Clean Version 2.0 - PDF - 184.69 KB
• Jardiance: Calculations ​and Analyses Underpinning Potential Upper Payment Limit (UPL) Values​ Tracked Version 2.0 - PDF - 111.03 KB
• Comments Received by March 4, 2026 on Jardiance UPL Amount and Methodology Document​:
  • Written Comment Packet​ - PDF - 1.15 MB
• Comments Received by April 6, 2026 on Jardiance: Calculations and Analyses Underpinning Potential Upper Payment Limit (UPL) Values:
  • Written Comment Packet  - PDF - 1.04 MB

Comments Received for 4/13/2026 Board Meeting:

Written Comment Packet - PDF - 3.6 MB

• ​AstraZeneca
• EACH/PIC
• Healthcare for All
• Patients Rising